Trial could ‘usher in a new era’ of affordable antibody therapies to protect against dangerous infectious diseases like Mers, ...

Eradivir's EV25 Therapeutic Reduces Advanced-Stage Influenza Viral Loads Faster, More Thoroughly in Preclinical Studies Than Current Therapies Nov. 19, 2024 — A research article shows that ...

The USDA plans to invest up to $100 million in research for bird flu therapies and vaccines. The U.S. will also import more ...

Traws Pharma Reports Positive Results from An Accepted Bird Flu Model for Anti-Viral Candidate, Tivoxavir Marboxil – (March 03, 2025) Traws Pharma, Inc. today announced positive topline results from ...

The market for these drugs includes antiviral medications such as neuraminidase inhibitors, polymerase acidic protein inhibitors, and combination therapies. The increasing incidence of seasonal flu ...

Antibody-based immune therapy could become a key weapon in the fight against bird flu after trials in monkeys successfully prevented severe illness and death from the infection. The preventative ...

Poster underscores Tivoxavir Marboxil’s potential for the treatment of bird flu, supported by 100% survival in a rodent ...

Additionally, collaborations between pharmaceutical companies and research institutions play a crucial role in accelerating drug development and bringing new therapies to market. The Influenza A Virus ...

A prophylactic antibody-based immune therapy protects monkeys against severe disease caused by H5N1 avian flu, University of Pittsburgh and NIH Vaccine Research Center researchers report today in ...

The USDA announced a $100 million investment to facilitate research into therapies and vaccines for bird flu. The funding will be available to vaccine makers, states, and universities. This initiative ...